180 related articles for article (PubMed ID: 35122631)
21. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.
Tran CG; Sherman SK; Scott AT; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2021 Feb; 28(2):732-741. PubMed ID: 32656719
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
[TBL] [Abstract][Full Text] [Related]
23. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
24. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.
Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
[TBL] [Abstract][Full Text] [Related]
25. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
Panzuto F; Severi C; Cannizzaro R; Falconi M; Angeletti S; Pasquali A; Corleto VD; Annibale B; Buonadonna A; Pederzoli P; Delle Fave G
J Endocrinol Invest; 2004 Jan; 27(1):6-11. PubMed ID: 15053236
[TBL] [Abstract][Full Text] [Related]
26. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
27. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
28. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
29. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
Chou WC; Hung YS; Hsu JT; Chen JS; Lu CH; Hwang TL; Rau KM; Yeh KY; Chen TC; Sun CF
Neuroendocrinology; 2012; 95(4):344-50. PubMed ID: 22343505
[TBL] [Abstract][Full Text] [Related]
30. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Matsumoto I; Otani K; Asari S; Goto T; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2017; 17(2):291-294. PubMed ID: 28043759
[TBL] [Abstract][Full Text] [Related]
31. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
32. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
33. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.
Miki M; Ito T; Hijioka M; Lee L; Yasunaga K; Ueda K; Fujiyama T; Tachibana Y; Kawabe K; Jensen RT; Ogawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):520-528. PubMed ID: 28334992
[TBL] [Abstract][Full Text] [Related]
34. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract][Full Text] [Related]
35. Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning Pancreatic Neuroendocrine Tumors.
Nanno Y; Toyama H; Matsumoto I; Uemura J; Asari S; Goto T; Lee D; Murakami T; Komatsu S; Yanagimoto H; Kido M; Ajiki T; Okano K; Takeyama Y; Fukumoto T
Ann Surg Oncol; 2023 Jun; 30(6):3493-3500. PubMed ID: 36795254
[TBL] [Abstract][Full Text] [Related]
36. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
[TBL] [Abstract][Full Text] [Related]
37. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
38. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
40. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
